You have 9 free searches left this month | for more free features.

City

Basel (1)

Freiburg (1)

Munster (1)

Condition

Acute Myeloid Leukemia (AML) Relapse (1)

Non-small Cell Lung Cancer (NSCLC) (1)

Overall Status

Active, not recruiting (1)

Completed (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

Philogen S.p.A. (2)

Collaborator

Boehringer Ingelheim (1)

Intervention

f16il2 (2)

bi 836858 (1)

nivolumab, fixed dose (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

f16il2

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

NSCLC (NSCLC) Trial in Basel (F16IL2, Nivolumab, fixed dose)

Active, not recruiting

Non-small Cell Lung Cancer (NSCLC)

F16IL2
Nivolumab, fixed dose

Basel, Switzerland

Basel University Hospital

Jul 19, 2022

Acute Myeloid Leukemia (AML) Relapse Trial in Freiburg, Münster (F16IL2, BI 836858)

Completed

Acute Myeloid Leukemia (AML) Relapse

F16IL2
BI 836858

Freiburg, Germany
+1 more

Apr 13, 2022